Coya Therapeutics, Inc. Announces Peer-Reviewed Publication of Phase 2a Clinical Trial Data for COYA 101 in Amyotrophic Lateral Sclerosis (ALS)
September 01, 2022 09:27 ET
|
Coya Therapeutics, Inc.
Phase 2a publication entitled “Combined Regulatory T-Lymphocyte and IL-2 Treatment is Safe, Tolerable, and Biologically Active for One Year in Persons with Amyotrophic Lateral Sclerosis” has been...
Coya Therapeutics Announces Peer-Reviewed Publication of its First-in-Class Regulatory T Cell-derived Exosomes and their Therapeutic Potential in Neurodegeneration and Inflammation Related Diseases
June 23, 2022 09:27 ET
|
Coya Therapeutics, Inc.
Regulatory T Cell (Treg)-derived exosome data have been published in the peer-reviewed journal Frontiers of Immunology Characterization of Treg-derived exosomes show Treg cells-conserved functional...
Coya Therapeutics Secures Option Agreement for Exclusive Worldwide Rights to Exosome Engineering Technology from Carnegie Mellon University
June 15, 2022 09:27 ET
|
Coya Therapeutics, Inc.
Proprietary technology generates Exosome Polymer Hybrids (EPHs) which allow for efficient and versatile method of customizing cargoes of Treg-derived exosomes using oligonucleotide tethers ...
Coya Therapeutics Secures $10 Million Financing to Advance Clinical and Pre-Clinical Pipeline of Regulatory T Cell Therapeutics
June 07, 2022 10:02 ET
|
Coya Therapeutics, Inc.
Coya Therapeutics’ clinical and biomarker data continue to demonstrate regulatory T cells (Tregs) ability to meaningfully dampen both systemic and neuroinflammation, thereby restoring the immune...